Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03918915 · ClinicalTrials.gov registry record · Phase 3
The Safety and Efficacy of SYD-101 in Children With Myopia
A Phase 3 study of Nearsightedness and Near Sightedness, sponsored by Sydnexis.
- Completed
- Registry status
- Phase 3
- Development phase
- 852
- Enrollment target
- 20
- Study locations
NCT03918915: Completed Phase 3 study of Nearsightedness and Near Sightedness, sponsored by Sydnexis.
NCT03918915 is a Phase 3 study of Nearsightedness and Near Sightedness that has completed, run by Sydnexis. The registered enrollment target is 852 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03918915, a Phase 3 study of Nearsightedness and Near Sightedness, has completed, sponsored by Sydnexis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 852 participants
- Enrollment target
- 20
- Study locations
Study Summary
Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of adults in Europe, Asia and the USA. Severe myopia is associated with an increased risk of developing other eye conditions such as glucoma, cataracts and retinal detachment, which may lead to blindness. Early treatment of myopia in children could help slow the condition and minimize the risk of complications later in life. This study investigates the use of SYD-101, an eye solution, in slowing-down the progression of myopia in children.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG SYD-101 0.01%
- DRUG SYD-101 0.03%
Study Locations (20)
California
- Site 143 - Irwindale
- Site 144 - Pasadena
- Site 148 - San Diego
- Site 104 - San Diego
- Site 110 - Santa Barbara
- Site 133 - Sunnyvale
Florida
- Site 122 - Fort Lauderdale
- Site 109 - Jupiter
- Site 119 - Sweetwater
- Site 120 - Tamarac
Colorado
- Site 130 - Colorado Springs
- Site 100 - Fort Collins
Connecticut
- Site 102 - Danbury
- Site 150 - Waterbury
Illinois
- Site 116 - Chicago
- Site 106 - Wilmette
Indiana
- Site 135 - Indianapolis
- Site 131 - Munster
Georgia
- Site 124 - Marietta
Kansas
- Site 137 - Pittsburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 852 participants |
| Start Date | 2019-04-24 |
| Est. Completion | 2025-05-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03918915
The ClinicalTrials.gov registry entry for NCT03918915 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 852 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (10% higher). The listed sponsor is Sydnexis, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Nearsightedness appearing as the primary indexed condition, and to 3 interventions - of which Vehicle is the first listed.
NCT03918915 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT03918915 about?
NCT03918915 is a clinical study titled "The Safety and Efficacy of SYD-101 in Children With Myopia". Myopia, or nearsightedness, is the most common eye disorder, often affecting more than 40% of adults in Europe, Asia and the USA. Severe myopia is associated with an increased risk of developing other eye conditions such as glucoma, cataracts and retinal detachment, which may lead to blindness. Earl...
What is the current status of trial NCT03918915?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 852 participants. The study started on 2019-04-24. Estimated completion is 2025-05-01.
What conditions does trial NCT03918915 study?
This clinical trial studies the following conditions: Nearsightedness, Near Sightedness.
What interventions are being tested in trial NCT03918915?
The interventions under investigation include: Vehicle (DRUG), SYD-101 0.01% (DRUG), SYD-101 0.03% (DRUG).
Who is sponsoring clinical trial NCT03918915?
This trial is sponsored by Sydnexis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03918915 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nearsightedness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.